$SPRB ($SPRB) is expected to release its quarterly earnings data on Monday, April 14th after market close, per Finnhub. Analysts are expecting revenue of $902,700 and ...
The average one-year price target for Spruce Biosciences (NasdaqCM:SPRB) has been revised to $137.19 / share. This is an increase of 2,045.14% from the prior estimate of $6.40 dated November 7, 2025.
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the most promising micro-cap stocks according to analysts. On February 18, Spruce Biosciences recently concluded successful Type B meetings with the FDA ...
Fintel reports that on October 21, 2025, Leerink Partners maintained coverage of Spruce Biosciences (NasdaqCM:SPRB) with a Market Perform recommendation. Analyst Price Forecast Suggests 92.13% ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Spruce Biosciences ( (SPRB)) has provided ...
Hong Kong-based Harbour BioMed on Sunday exercised its warrant to acquire the common stock in Spruce Biosciences Inc. (NASDAQ: SPRB). Following this transaction, Harbour BioMed holds approximately 3.8 ...
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results